Viatris filed its first Paragraph IV certification against a semaglutide patent in December 2021 — nearly four years before Novo Nordisk lost the resulting court fight in July 2025, and roughly a decade before Ozempic's core patents expire. That gap is the whole point: a Paragraph IV filing is a generic manufacturer's public, dated declaration that a brand patent is invalid or won't be infringed, filed years before any product reaches a pharmacy shelf. Across the FDA's Paragraph IV certification list, we count 1,608 filings since the mechanism's earliest recorded entries, and the pattern of who challenges what — and when — is a legible early-warning system for which brand-name franchises are about to face real competition.
What the data shows
Annual filing volume has been remarkably stable since the 2003 Medicare Modernization Act reforms cleaned up the process: after a 2004–2009 ramp (48 to 97 filings/year, likely a backlog effect as ANDA activity caught up with the new rules), the index settles into a broader but still active range of 39–80 filings per year from 2010 through 2025 — a 2010 rebound to 80 and a 2020 trough of 39 bookend the period, but there is no structural decline. The most-challenged molecules in the dataset are dominated by controlled substances and chronic-therapy drugs with high-volume ANDA interest: methylphenidate hydrochloride (12 filings), levothyroxine sodium (10), and eight each for oxycodone, ropinirole, testosterone, hydromorphone, and minocycline — all molecules with multiple brand formulations (extended-release, patches, combinations) that generate separate challenges per dosage form.
Semaglutide is the clearest live example of the leading-indicator effect: public FDA filings show 7 separate Paragraph IV filings against Ozempic, Wegovy, and Rybelsus between December 2021 and March 2026, naming qualifying-patent expiries as late as 2033–2041. Viatris's challenge, filed in 2021, became public knowledge in this dataset three years before the resulting Novo Nordisk v. Viatris litigation concluded in Viatris's favor in July 2025 — a result Fierce Pharma called a step that "clears a hurdle for potential Wegovy generic" entry [1]. Anyone tracking the Paragraph IV list in 2022 had a multi-year lead on that market-moving news.
Why the mechanism works as a signal
Under Hatch-Waxman, a generic filer who submits a Paragraph IV certification must notify the patent holder within 20 days, and that notice becomes discoverable and, eventually, publicly listed by the FDA [2]. The first successful challenger earns 180 days of marketing exclusivity against other generics — a reward large enough that filers commit years before launch is even legally possible, often immediately after a drug's five-year (small molecule) or twelve-year (biologic-adjacent) data exclusivity window opens [3]. That incentive structure is precisely why the filing date front-runs the news cycle: litigation, settlement, and eventual generic launch are downstream events that can take three to six years to resolve, as they did for Ozempic and are still doing for Wegovy [4].
Caveats
The index's decision_status field (Eligible, Extinguished, Deferred, Non-Forfeiture, and combinations) is FDA's own 180-day-exclusivity forfeiture bookkeeping, not a signal of litigation outcome — a filing being "Extinguished" often just means exclusivity was forfeited or superseded by a later filer, not that the generic lost. The date_of_first_piv field is a mix of exact dates and legacy buckets like "Pre-MMA" (240 records, pre-2003) and "PIV received prior to 2/5/2009," which cannot be resolved to a single year. And a Paragraph IV filing is a bet, not a verdict: many are settled confidentially, some are withdrawn, and brand holders win a meaningful share of the underlying patent litigation.
Why this matters: because the filing precedes launch by years, a Paragraph IV list is one of the few places where a generic manufacturer's competitive intent toward a specific brand becomes public record before it shows up in an earnings call, a settlement press release, or an FDA approval. Tracked systematically by molecule and qualifying-patent expiry, it turns "which brands lose exclusivity next" from a lagging financial-news question into a forward-looking one.